Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine in Infants Aged 3 to 5 Months
NCT07505810Phase 3Recruiting
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Mar 2026
- Primary completion
- Apr 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of diphtheria, tetanus, and acellular pertussis vaccine + haemophilus influenzae type b vaccine + quadrivalent meningococcal conjugate vaccine in meningococcal meningitis, sponsored by Sinovac Biotech Ltd.. Started Mar 2026; status: recruiting.
02
Drugs
diphtheria, tetanus, and acellular pertussis vaccine + haemophilus influenzae type b vaccine + quadrivalent meningococcal conjugate vaccine
03
Conditions
meningococcal meningitis
Beyond the preview
Go deeper on NCT07505810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07505810.